

Reference:	FOI.17034.25
Subject:	Prostate cancer
Date of Request:	9 April 2025

Requested:

I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023 - December 31, 2024. Specifically, I am seeking the following information:

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
3. Number of Patients for Whom Hormone Therapy Was Continued for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)
4. Number of patients for Whom Docetaxel was Initiated for ICD-10 C61 / M0 and M1-M1c (both localised and metastatic)

The hormone therapies of interest are:

- a. ADT* alone
- b. Abiraterone (Zytiga) in combination with any ADT
- c. Abiraterone (Zytiga) – no ADT
- d. Enzalutamide (Xtandi) in combination with any ADT
- e. Enzalutamide (Xtandi) – no ADT
- f. Apalutamide (Erleada) in combination with any ADT
- g. Darolutamide (Nubeqa) in combination with any ADT
- h. Darolutamide (Nubeqa) in combination with any ADT with docetaxel
- i. Docetaxel in combination with any ADT

*By ADT we mean any of the following drugs: Goserelin (Zoladex), Leuprorelin acetate (Prostap), Triptorelin (Decapeptyl), Buserelin acetate (Suprefact), Degarelix (Firmagon), Relugolix (Orgovyx).

I would appreciate it if you could provide the information in an electronic format, preferably in the ***attached spreadsheet format.***

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The UHB is unable to provide you with all of the information requested for questions 2 and 3 and also part of questions 1 and 4 as the UHB's Pharmacy system does not record the indication for treatment and is unable to link the dispensing data to the ICD-10 codes requested. Therefore, in order to provide you with all of the information requested, the UHB would be required to conduct a manual trawl of all cancer patients' medical records to establish the type of cancer diagnosed, and the therapies used to treat the patients, to identify any information that would fulfil your request, as this information is not recorded centrally.

Additionally, the ChemoCare system, does not hold the data to the level of detail required, and a further manual trawl of patient records would be required to provide the data as requested.

The UHB can confirm that four hundred and eighty-three (483) patients have been identified in response to your request, for the period 1 January 2023 to 31 December 2024. Therefore, to provide you with the exact information being requested, conducting the search would far exceed the 'appropriate limit', costing the UHB the following:

483 @ 15 minutes per item = 120.75 hours
120.75 hours @ £25 per hour = £3,018.75

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds within the attached spreadsheet, at Attachment 1.

Please note, the UHB is unable to complete the template exactly as requested due to the information being inaccessible, the UHB has therefore adapted the spreadsheet in accordance with the information held.